Back to results
US 9,040,044 B2Granted
Compositions and methods for treating and diagnosing cancer
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsAustin L. Gurney, Aaron K. Sato
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsAustin L. Gurney, Aaron K. Sato
Estimating the term…
The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
A method of inhibiting beta-catenin signaling in a cell, comprising contacting the cell with an effective amount of an antibody that specifically binds the extracellular domain of a human leucine-rich repeat-containing G protein-coupled receptor (LGR) protein, wherein the antibody:
A method of inhibiting beta-catenin signaling in a tumor cell in a subject, comprising administering to the subject a therapeutically effective amount of an antibody that specifically binds the extracellular domain of a human leucine-rich repeat-containing G protein-coupled receptor (LGR) protein, wherein the antibody:
Dependencies are inferred from the claim text.